替加环素
肝损伤
医学
内科学
生物
微生物学
抗生素
作者
Jeeva Elizabeth Thomas,M Manish Mohan,Rinku Elsa Reji
出处
期刊:International journal of medical science and clinical research studies
[Everant Journals]
日期:2024-07-04
卷期号:04 (07)
标识
DOI:10.47191/ijmscrs/v4-i07-01
摘要
Tigecycline, the inaugural glycylcycline antibiotic in clinical use, is experiencing rising global utilization owing to its effectiveness against multidrug-resistant (MDR) bacteria. Although gastrointestinal side effects like nausea and vomiting are more prevalent, it is important to recognize that tigecycline can also lead to liver injury. The manufacturer has issued a warning regarding tigecycline's potential to elevate total bilirubin (TB) and transaminase levels. [1] We present the case of a 74-year-old female with a history of multiple comorbidities who developed severe hepatotoxicity following tigecycline therapy for a complicated intra-abdominal infection. The patient shows an abnormal liver function test with hyperbilirubinemia. Later on she developed jaundice. This case underscores the importance of considering TILI in patients receiving tigecycline, particularly those with preexisting liver disease or receiving other potentially hepatotoxic medications.
科研通智能强力驱动
Strongly Powered by AbleSci AI